First Trust Advisors LP Purchases 183,038 Shares of Corcept Therapeutics Incorporated $CORT

First Trust Advisors LP grew its position in Corcept Therapeutics Incorporated (NASDAQ:CORT) by 34.1% in the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 720,224 shares of the biotechnology company’s stock after buying an additional 183,038 shares during the quarter. First Trust Advisors LP owned 0.68% of Corcept Therapeutics worth $59,858,000 as of its most recent SEC filing.

Other institutional investors and hedge funds also recently made changes to their positions in the company. Clearstead Advisors LLC increased its stake in Corcept Therapeutics by 163.6% in the third quarter. Clearstead Advisors LLC now owns 311 shares of the biotechnology company’s stock valued at $26,000 after acquiring an additional 193 shares during the last quarter. Hantz Financial Services Inc. raised its position in Corcept Therapeutics by 598.5% during the third quarter. Hantz Financial Services Inc. now owns 461 shares of the biotechnology company’s stock valued at $38,000 after purchasing an additional 395 shares in the last quarter. Bessemer Group Inc. lifted its stake in Corcept Therapeutics by 119.2% during the third quarter. Bessemer Group Inc. now owns 629 shares of the biotechnology company’s stock worth $53,000 after purchasing an additional 342 shares during the last quarter. Salomon & Ludwin LLC bought a new stake in Corcept Therapeutics during the third quarter worth $56,000. Finally, Employees Retirement System of Texas acquired a new stake in shares of Corcept Therapeutics in the 2nd quarter valued at $52,000. Institutional investors own 93.61% of the company’s stock.

Trending Headlines about Corcept Therapeutics

Here are the key news stories impacting Corcept Therapeutics this week:

• Neutral Sentiment: Short‑interest reports for early March show anomalous zero/NaN values and appear unreliable; there’s no clear evidence of a material short squeeze or buildup from the published figures. Short Interest Details
• Negative Sentiment: Holzer & Holzer filed an investor class action alleging Corcept made false/misleading statements and omitted material facts about relacorilant clinical trials and the odds of FDA approval — a direct legal claim tied to the company’s core drug program that could lead to damages, discovery of internal documents, and management distraction. Holzer & Holzer Investor Alert
• Negative Sentiment: Multiple plaintiff firms (Hagens Berman, Pomerantz, Bernstein Liebhard, Schall, Bragar Eagel & Squire, others) have announced or are soliciting participants in the same or related securities suits covering Oct 31, 2024–Dec 30, 2025 — the proliferation of firms increases filing activity and the chance of consolidated, high‑stakes litigation. Hagens Berman Alert
• Negative Sentiment: Business Wire and other notices remind investors of the April 21, 2026 lead‑plaintiff deadline — concentrated deadlines typically accelerate filings and media attention and can drive short‑term selling as investors price in legal uncertainty. Business Wire Reminder
• Negative Sentiment: Additional firm notices (PR Newswire, Law Offices of Howard G., Rosen, The Gross Law Firm, DJS Law Group, etc.) amplify outreach and may increase the probability of class consolidation and settlement pressure on Corcept. Investors should monitor filings, any company responses, and potential disclosures about trial data or internal communications. PR Newswire: Litigation Notice

Analyst Ratings Changes

A number of equities analysts have recently commented on CORT shares. UBS Group started coverage on Corcept Therapeutics in a report on Tuesday, December 16th. They set a “neutral” rating and a $95.00 price target for the company. Truist Financial set a $50.00 target price on Corcept Therapeutics in a research report on Wednesday, December 31st. HC Wainwright lowered their target price on Corcept Therapeutics from $105.00 to $67.00 and set a “buy” rating for the company in a research note on Friday, February 20th. Weiss Ratings reissued a “hold (c)” rating on shares of Corcept Therapeutics in a report on Monday, December 29th. Finally, Canaccord Genuity Group raised their price target on shares of Corcept Therapeutics from $99.00 to $100.00 and gave the company a “buy” rating in a research note on Friday, January 23rd. Four research analysts have rated the stock with a Buy rating, two have assigned a Hold rating and two have assigned a Sell rating to the stock. Based on data from MarketBeat, Corcept Therapeutics has an average rating of “Hold” and a consensus price target of $77.17.

Insider Buying and Selling

In related news, insider William Guyer sold 8,233 shares of Corcept Therapeutics stock in a transaction that occurred on Wednesday, March 4th. The shares were sold at an average price of $35.99, for a total transaction of $296,305.67. Following the sale, the insider directly owned 2,231 shares in the company, valued at $80,293.69. This trade represents a 78.68% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. In the last 90 days, insiders have sold 48,233 shares of company stock worth $1,817,306. 20.50% of the stock is owned by company insiders.

Corcept Therapeutics Trading Down 1.3%

Shares of CORT stock opened at $33.54 on Wednesday. Corcept Therapeutics Incorporated has a twelve month low of $28.66 and a twelve month high of $117.33. The stock’s fifty day simple moving average is $37.94 and its 200 day simple moving average is $63.87. The company has a quick ratio of 2.85, a current ratio of 2.92 and a debt-to-equity ratio of 0.01. The firm has a market capitalization of $3.57 billion, a P/E ratio of 40.90 and a beta of 0.29.

Corcept Therapeutics (NASDAQ:CORT) last posted its earnings results on Tuesday, February 24th. The biotechnology company reported $0.20 EPS for the quarter, missing the consensus estimate of $0.33 by ($0.13). Corcept Therapeutics had a net margin of 12.96% and a return on equity of 15.19%. The firm had revenue of $202.13 million during the quarter, compared to the consensus estimate of $254.94 million. During the same quarter in the prior year, the business posted $0.26 earnings per share. Corcept Therapeutics’s revenue for the quarter was up 11.1% compared to the same quarter last year. As a group, sell-side analysts predict that Corcept Therapeutics Incorporated will post 1.36 EPS for the current fiscal year.

Corcept Therapeutics Profile

Corcept Therapeutics is a clinical-stage biopharmaceutical company focused on discovering and developing drugs that modulate the effects of cortisol, a hormone implicated in a range of severe metabolic, oncologic and psychiatric disorders. The company’s scientific platform centers on selectively targeting the glucocorticoid receptor to counteract the harmful consequences of excess cortisol, a strategy designed to address diseases with significant unmet medical needs.

The company’s flagship marketed product, Korlym (mifepristone), is approved in the United States for the treatment of hyperglycemia secondary to Cushing’s syndrome in patients who have type 2 diabetes or glucose intolerance and are not candidates for surgery.